243 related articles for article (PubMed ID: 34036319)
21. Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice.
Fernández-Ruiz M; Bodro M; Gutiérrez Martín I; Rodriguez-Álvarez R; Ruiz-Ruigómez M; Sabé N; López-Viñau T; Valerio M; Illaro A; Fortún J; Salto-Alejandre S; Cordero E; Fariñas MDC; Muñoz P; Vidal E; Carratalà J; Goikoetxea J; Ramos-Martínez A; Moreno A; Aguado JM;
Transplantation; 2023 Mar; 107(3):762-773. PubMed ID: 36367924
[TBL] [Abstract][Full Text] [Related]
22. Association between drug tolerability and medical resource use in prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplant.
Gao X; Marks DI; Schlamm HT; Ji X; Stephens JM; Tarallo M
J Med Econ; 2013 Aug; 16(8):1061-70. PubMed ID: 23730943
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of a primary antifungal prophylaxis protocol for preventing invasive mold infections after allogeneic hematopoietic stem cell transplantation.
Herity LB; Cruz OA; Aziz MT
J Oncol Pharm Pract; 2022 Jun; 28(4):794-804. PubMed ID: 33906508
[TBL] [Abstract][Full Text] [Related]
24. Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole.
Maertens J; Selleslag D; Heinz WJ; Saulay M; Rahav G; Giladi M; Aoun M; Kovanda L; Kaufhold A; Engelhardt M; Cornely OA; Herbrecht R; Ullmann AJ
Mycoses; 2018 Nov; 61(11):868-876. PubMed ID: 30035825
[TBL] [Abstract][Full Text] [Related]
25. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
[TBL] [Abstract][Full Text] [Related]
26. Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial.
Kontoyiannis DP; Selleslag D; Mullane K; Cornely OA; Hope W; Lortholary O; Croos-Dabrera R; Lademacher C; Engelhardt M; Patterson TF
J Antimicrob Chemother; 2018 Mar; 73(3):757-763. PubMed ID: 29194488
[TBL] [Abstract][Full Text] [Related]
27. The Use of Voriconazole as Primary Prophylaxis for Invasive Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation: A Single Center's Experience.
Atoui A; Omeirat N; Fakhreddine O; El Alam R; Kanafani Z; Abou Dalle I; Bazarbachi A; El-Cheikh J; Kanj SS
J Fungi (Basel); 2021 Oct; 7(11):. PubMed ID: 34829213
[TBL] [Abstract][Full Text] [Related]
28. Clinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir.
Terrier J; Zanella MC; Masouridi-Levrat S; Kronig I; Chalandon Y; Vernaz N; Van Delden C; Papanicolaou G; Neofytos D
Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33782007
[TBL] [Abstract][Full Text] [Related]
29. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.
Wingard JR; Carter SL; Walsh TJ; Kurtzberg J; Small TN; Baden LR; Gersten ID; Mendizabal AM; Leather HL; Confer DL; Maziarz RT; Stadtmauer EA; Bolaños-Meade J; Brown J; Dipersio JF; Boeckh M; Marr KA;
Blood; 2010 Dec; 116(24):5111-8. PubMed ID: 20826719
[TBL] [Abstract][Full Text] [Related]
30. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness.
Cadena J; Levine DJ; Angel LF; Maxwell PR; Brady R; Sanchez JF; Michalek JE; Levine SM; Restrepo MI
Am J Transplant; 2009 Sep; 9(9):2085-91. PubMed ID: 19645709
[TBL] [Abstract][Full Text] [Related]
31. Why do lung transplant patients discontinue triazole prophylaxis?
Pennington KM; Razonable RR; Peters S; Scott JP; Wylam M; Daly RC; Kennedy CC
Transpl Infect Dis; 2019 Jun; 21(3):e13067. PubMed ID: 30866168
[TBL] [Abstract][Full Text] [Related]
32. Antifungal prophylaxis in haematology patients: the role of voriconazole.
Hicheri Y; Cook G; Cordonnier C
Clin Microbiol Infect; 2012 Apr; 18 Suppl 2():1-15. PubMed ID: 22409648
[TBL] [Abstract][Full Text] [Related]
33. Risk Factors and Outcomes of Invasive Fungal Infections in Allogeneic Hematopoietic Cell Transplant Recipients.
Miceli MH; Churay T; Braun T; Kauffman CA; Couriel DR
Mycopathologia; 2017 Jun; 182(5-6):495-504. PubMed ID: 28124219
[TBL] [Abstract][Full Text] [Related]
34. Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre.
Bowen CD; Tallman GB; Hakki M; Lewis Ⅱ JS
Mycoses; 2019 Aug; 62(8):665-672. PubMed ID: 31050373
[TBL] [Abstract][Full Text] [Related]
35. Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies.
Hamed K; Engelhardt M; Kovanda LL; Huang JJ; Yan J; Aram JA
Sci Rep; 2023 Apr; 13(1):6730. PubMed ID: 37185921
[TBL] [Abstract][Full Text] [Related]
36. The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom.
Floros L; Pagliuca A; Taie AA; Weidlich D; Rita Capparella M; Georgallis M; Sung AH
J Med Econ; 2020 Jan; 23(1):86-97. PubMed ID: 31262225
[No Abstract] [Full Text] [Related]
37. Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center.
Van Matre ET; Evans SL; Mueller SW; MacLaren R; Fish DN; Kiser TH
Ann Clin Microbiol Antimicrob; 2019 Mar; 18(1):13. PubMed ID: 30894179
[TBL] [Abstract][Full Text] [Related]
38. Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.
Bow EJ; Vanness DJ; Slavin M; Cordonnier C; Cornely OA; Marks DI; Pagliuca A; Solano C; Cragin L; Shaul AJ; Sorensen S; Chambers R; Kantecki M; Weinstein D; Schlamm H
BMC Infect Dis; 2015 Mar; 15():128. PubMed ID: 25887385
[TBL] [Abstract][Full Text] [Related]
39. Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation.
Marks DI; Liu Q; Slavin M
Expert Rev Anti Infect Ther; 2017 May; 15(5):493-502. PubMed ID: 28335642
[TBL] [Abstract][Full Text] [Related]
40. [Invasive aspergillosis in solid organ transplantation].
Silva JT; Torre-Cisneros J; Aguado JM
Rev Iberoam Micol; 2018; 35(4):206-209. PubMed ID: 30467000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
